Skip to main content

Table 1 Baseline Characteristics

From: Virologic versus immunologic monitoring and the rate of accumulated genotypic resistance to first-line antiretroviral drugs in Uganda

Characteristic IM (n = 998) VLM (n = 441) P-value
Age (IQR yrs) 36.2 (31.5 – 41.3) 35 (30 – 41) 0.002
Gender    0.667
 Female 680 (68%) 306 (69%)  
 Male 318 (32%) 135 (31%)  
Baseline CD4 (IQR cells/μl) 86 (29–154) 101.5 (30.5-170) 0.330
WHO Stage (n = 996)   <0.0001
 WHO Stage I 18 (2%) 2 (1%)  
 WHO Stage II 233 (23%) 49 (11%)  
 WHO Stage III 478 (48%) 257 (58%)  
 WHO Stage IV 267 (27%) 133 (30%)  
Hb (IQR) 11.3 (10.0 – 12.7) 11.7 (10.6 – 13.0) 0.001
BMI (IQR kg/m2) 20.2 (18.2 – 22.5) 20.2 (18.3 – 22.6) 0.917
ART Regimen    0.726
d4T/3TC/NVP 721 (72%) 325 (74%)  
d4T/3TC/EFV 3 (0.5%) 0  
ZDV/3TC/NVP 2 (0.5%) 0  
ZDV/3TC/EFV 272 (27%) 116 (26%)  
  1. IM: Immunologically monitored; VLM: Virologically monitored; IQR: Interquartile Range; Hb: Hemoglobin; BMI: Body mass index; ART: antiretroviral therapy; d4T: stavudine; 3TC: lamivudine; ZDV: zidovudine; NVP: nevirapine; EFV: efavirenz.